



News Updates: April 30, 2014

Patents/ Compulsory Licensing/ Intellectual Property

Publication: The Economic Times

Edition: National

Date: April 30, 2014

Headline: [Pfizer isolated in campaign to push US to downgrade India](#)

Synopsis: A grouping of top domestic drugmakers, Indian Pharma Alliance, has told the government that global pharma giant 'Pfizer Inc is getting isolated in its campaign' to push the US to 'downgrade India' to a 'priority foreign country' in a review of its intellectual property (IP) regime. The label is the lowest classification any country can find itself in on a US-made rating scale for intellectual property protection. At worst, it can trigger trade sanctions against India by the American government. In one of their sharpest attacks on the company yet, Indian drug makers allege in a letter to various government arms that Pfizer's insistence to downgrade India could stem from its failure to strike successful tieups with generic drug companies in India unlike most of its peers, its dried pipeline of new drugs, and its perceived philosophy that the US IP model is the only right one.

Similar report in-

The Financial Express- [Pfizer's weak drug pipeline fuels hunger for AstraZeneca](#)

Publication: Business Standard

Edition: National

Date: April 30, 2014

Headline: [US is not as bullish on India as it used to be: Sanjay Puri](#)

Synopsis: The United States India Political Action Committee (USINPAC) claims to represent the political voice of 2.7 million American Indians. USINPAC Chairman Sanjay Puri, in an interview, says the US is concerned about India's taxation policy, intellectual property rights (IPR) issues, etc.

Drug pricing

Publication: The Hindu Business Line

Edition: National

Date: April 29, 2014

Headline: [Cipla gets Rs 81-cr notice for overcharging](#)

Synopsis: Drugmaker Cipla confirmed that it had received a notice of Rs 81 crore for overcharging on Ciplox eye drops, this January. The notice from the National Pharmaceutical Pricing Authority was for the period May 2008 to November 2013. However, the company added: "the notice was erroneous because we were complying with the Government announced prices effective April 2010."

Similar report in-

Business Today- [Govt penalty demand on 'overcharging' not tenable, says Cipla](#)

General Industry

Publication: The Economic Times

Edition: National

Date: April 30, 2014

Headline: [Sun Pharma, Ranbaxy deal hits fresh roadblock; stock slip 2% each](#)

Synopsis: Shares of Sun Pharma and Ranbaxy Laboratories Ltd slipped over 2 per cent each in trade on Wednesday, after the Andhra Pradesh High Court has asked stock exchanges not to approve Sun Pharmaceutical's all-share transaction to buy Ranbaxy BSE -1.98 % Laboratories until it decides on a petition alleging insider trading in the \$4 billion (Rs 24,000-crore) deal. On Friday, the court admitted a writ petition by a group of investors who claimed that entities with prior knowledge of the deal illegally profited to the extent of Rs 285 crore.

Similar reports in-

Mint- [High court orders status-quo on Sun Pharma-Ranbaxy merger](#)

Business Standard- [Sun Pharma-Ranbaxy deal: Court orders interim status quo on merger](#)

The Times of India- [Sun-Ranbaxy merger runs into legal wrangle](#)

The Financial Express- [Insider trading? HC orders status quo on Sun Pharma-Ranbaxy deal](#)

NDTV- [Sun Pharma-Ranbaxy merger put on hold by Andhra Pradesh High Court](#)

Publication: The Economic Times

Edition: National

Date: April 30, 2014

Headline: [Glenmark Pharmaceuticals's monoclonal antibody for pain entering human trials](#)

Synopsis: Glenmark Pharmaceuticals today said its novel monoclonal antibody for potential treatment of chronic pain is entering human trials. The company has completed preclinical studies and Phase 1 enabling preclinical development programme for GBR 900; it has filed a Phase I clinical trial application with the MHRA, UK, Glenmark Pharma said in a BSE filing.

Similar reports in-

Business Standard- [Glenmark Pharmaceuticals starts human trials for GBR 900](#)

The Hindu Business Line- [Glenmark monoclonal antibody trial](#)

Pharmabiz- [Glenmark's novel monoclonal antibody GBR 900 for chronic pain enters human trial](#)